|1.||Stoll, K D: 3 articles (11/2004 - 05/2000)|
|2.||Volz, H P: 2 articles (02/2001 - 05/2000)|
|3.||Möller, H J: 2 articles (02/2001 - 05/2000)|
|4.||Kar, Sujit Kumar: 1 article (12/2015)|
|5.||Garg, Kabir: 1 article (12/2015)|
|6.||Jakuszkowiak-Wojten, Katarzyna: 1 article (09/2015)|
|7.||Zawada, Karolina: 1 article (09/2015)|
|8.||Warchala, Anna: 1 article (09/2015)|
|9.||Krysta, Krzysztof: 1 article (09/2015)|
|10.||Krupka-Matuszczyk, Irena: 1 article (09/2015)|
|1.||Somatoform Disorders (Somatoform Disorder)
05/01/2000 - "The results of this first-placebo-controlled study in somatoform disorders suggest efficacy of opipramol in this indication but need replication."
05/01/2000 - "Therefore, the efficacy of opipramol in somatoform disorders was evaluated using adequate clinical trial methods. "
05/01/2000 - "Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial."
12/01/1998 - "[Opipramol in anxiety and somatoform disorders. "
09/01/2015 - "it may be used as a premedication in the evening prior to surgery, positive results are also observed in psychopharmacological treatment with opipramol in somatoform disorders, symptoms of depression can be significantly reduced in the climacteric syndrome. "
|2.||Anxiety Disorders (Anxiety Disorder)
12/01/2006 - "Opipramol 2-HCl (OP) is used for therapy of general somatoform and anxiety disorders. "
11/01/2004 - "Opipramol, which, apart from a sigma-1- and 2-receptor liability, also possesses histamine-H(1)-antagonistic properties in connection with lower affinities for D(2) and 5-HT(2A) showed broad efficacy in generalized anxiety disorder and somatoform disorders. "
02/01/2001 - "Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group."
12/01/2015 - "Mania, a probable adverse drug reaction of opipramol in a patient with generalized anxiety disorder."
09/01/2015 - "Mania may be induced not only in bipolar patients treated with opipramol, but it can be an adverse drug reaction in generalized anxiety disorder. "
|3.||Depressive Disorder (Melancholia)
01/01/1989 - "The corroboration of the data of clinical and paraclinical observations with the psychologic examination and the computer-processed data reveals the clinical efficacy of Insidon--Geigy in neurotic depression, its good tolerance and low incidence of side effects."
05/01/1963 - "[THERAPEUTIC EFFECTS OF INSIDON IN DEPRESSIVE DISORDERS IN CHILDREN]."
12/01/2006 - "Introduction of sustained release opipramol dihydrochloride matrix tablets as a new approach in the treatment of depressive disorders."
05/01/1966 - "[Comparative evaluation of the antidepressive properties of opipramol, imipramine and placebo in neurotic depression]."
01/01/1966 - "A double-blind comparative study of opipramol and amitriptyline in neurotic and endogenous depressions."
|5.||Schizophrenia (Dementia Praecox)
11/01/2004 - "So far, sigma-ligands have been investigated for several indications in human studies in functional diarrhea as a model of somatoform disorder (igmesine), depression (igmesine, opipramol), anxiety (opipramol and--in animal models--siramisine), schizophrenia (panamasine, SL 82.0715, rimcazole, DuP 734, BMY 14 802), and somatoform disorders (opipramol). "